Frequently asked questions

Find answers to some of the frequently asked questions about CONTRAVE below.

Through the CurAccess Patient Support Program, patients will pay $99/month or less for CONTRAVE + FREE Shipping to their home. Our best-in-class savings and support program can help your patients save on their CONTRAVE prescription.

Learn more

In 3 clinical trials, there was significantly greater weight loss observed in patients using CONTRAVE compared to those on diet and exercise alone at the first time point assessed, which was 4 weeks after the initiation of therapy.1,2

View study results

Patients can get CONTRAVE for $99/month or less + FREE Shipping through the CurAccess Patient Support Program. We partner with Lombard Pharmacy and Ridgeway Pharmacy, so your patients can have CONTRAVE delivered directly to their door.

Get started today

Once you have submitted the prescription to Lombard Pharmacy or Ridgeway Pharmacy, and the patient has confirmed insurance and mailing details with the pharmacy, your patient will typically receive CONTRAVE within 3-5 business days.

To rush an order, patients may opt to pay for expedited delivery.

The CONTRAVE Savings Coupon Card can help eligible patients with or without insurance coverage save on their prescription.

View eligibility requirements

In the COR-1, COR-BMOD, and COR-Diabetes trials, peak weight loss, on average, was achieved after patients had been on CONTRAVE for 36 weeks. On average, patients maintained this weight loss through 56 weeks.1

View study results

Medicare Part D and TRICARE beneficiaries are eligible for the CONTRAVE Savings Coupon Card; however, terms and conditions apply.

View eligibility requirements

The most common adverse reactions reported (≥5%) include: nausea (32.5%), constipation (19.2%), headache (17.6%), vomiting (10.7%), dizziness (9.9%), insomnia (9.2%), dry mouth (8.1%), and diarrhea (7.1%).1

Common GI-related adverse events were generally transient in nature and quickly resolved.2-4

GI=gastrointestinal.

See additional safety information

CONTRAVE, a combination of naltrexone HCl and bupropion HCl, targets the hypothalamus and mesolimbic reward system to give patients more control of their eating.1,5*

Unlike other weight-loss medications, CONTRAVE is not a controlled substance, scheduled drug, or stimulant.1,6

*The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.1

Learn how CONTRAVE works

Your patients can register for the CONTRAVE Savings Coupon Card at www.contrave.com/save. If they are having trouble signing up online, they can call 1-800-905-5576 for assistance.

Use this checklist to help collect the information most often needed to submit a PA for CONTRAVE.

The dose of CONTRAVE is slowly increased over time to help patients adjust to their medication. Patients with hepatic or renal impairment, or those taking certain other medications, may need to take a different dose.1

Review dosing information

Yes, you can use CONTRAVE in your patients with renal impairment. Dosing adjustments are needed for patients with moderate or severe renal impairment. CONTRAVE is not recommended for use in patients with end-stage renal disease.1

View dosing adjustments

During the clinical trial program, there was no weaning period. Patients stopped the medication at the end of their participation in the study. There did not appear to be any increase in adverse events following the end of the study.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References:

  1. CONTRAVE (naltrexone HCI and bupropion HCI) [prescribing information]. Brentwood, TN: Currax Pharmaceuticals LLC; 2021.
  2. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
  3. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120.
  4. Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016;6(5):305-312.
  5. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196.
  6. QSYMIA [prescribing information]. Campbell, CA: VIVUS, Inc; 2020.